Peptides — AI Isn’t an Inventor, It’s an Accelerator.

In recent years, we’ve heard a lot about AI transforming medicine. Terms like mRNA and peptides often appear in that context, which can make them seem like entirely new inventions.In reality, both have been studied and used for decades. mRNA functions as a kind of blueprint inside our cells, while peptides are the molecules created from those instructions. Technologies like mRNA vaccines or peptide-based drugs are built on long-standing biological mechanisms, not sudden breakthroughs.What AI has changed is the speed of development. Instead of slowly narrowing down possibilities through trial and experience, researchers can now explore vast combinations of molecular designs much more quickly. In that sense, AI is less an inventor and more an accelerator.Using examples like GLP-1 and semaglutide, this episode looks at how naturally occurring systems in the body, engineered molecules, and final medical products are connected. It also touches on how insulin and appetite regulation fit into the picture, helping explain why some of these drugs affect both blood sugar and body weight.The broader point is simple: what looks like a sudden innovation is often the result of many years of incremental work, brought into practical use by advances in technology.